MedDataX Logo

Malignancies in Transplanted Patients

NCT ID: NCT02241564

Last Updated: 2017-10-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-11-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the project is to improve the overall treatment and outcome of renal, pancreas or liver transplanted patients who have encountered a malignancy by a structured treatment program for diagnosis and treatment of the malignancy, optimization of the immunosuppressive treatment, follow-up and evaluation of the program.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Immunosuppression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Malignancy post transplantation

Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection

Intervention Type OTHER

Switch from calcineurin inhibitor to an mTOR inhibitor

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection

Intervention Type OTHER

Switch from calcineurin inhibitor to an mTOR inhibitor

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients willing and capable of giving written informed consent of participation in the project
* Patients with a previous diagnosed or presently diagnosed or reoccurrence of a malignancy (other then basal cell carcinoma)

Exclusion Criteria

* Patients with a primary liver cancer as cause of the transplantation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Uppsala University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tomas Lorant

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Surgery, Section of Transplantation Surgery, Uppsala University Hospital

Uppsala, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Hellstrom V, Lorant T, Dohler B, Tufveson G, Enblad G. High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer. Transplantation. 2017 Jun;101(6):1295-1302. doi: 10.1097/TP.0000000000001225.

Reference Type BACKGROUND
PMID: 27163539 (View on PubMed)

Hellstrom VC, Enstrom Y, von Zur-Muhlen B, Hagberg H, Laurell A, Nyberg F, Backman L, Opelz G, Dohler B, Holmberg L, Tufveson G, Enblad G, Lorant T. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation - experiences from a prospective, clinical, observational study. Acta Oncol. 2016 Jun;55(6):774-81. doi: 10.3109/0284186X.2015.1130855. Epub 2016 Jan 29.

Reference Type DERIVED
PMID: 26824275 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MALTX-001

Identifier Type: -

Identifier Source: org_study_id